| Patent application number | Description | Published |
|---|
| 20090081658 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 03-26-2009 |
| 20090305900 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH LONGEVITY - The present invention relates to the selection of a set of SNP markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's longevity, their protection against age-related diseases and/or their response to a particular drug or drugs. | 12-10-2009 |
| 20100081129 | Genemap of the human genes associated with crohn's disease - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-01-2010 |
| 20100099083 | CROHN DISEASE SUSCEPTIBILITY GENE - The present invention relates to the ATG16l1 gene and genetic variants associated with Crohn's disease. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-22-2010 |
| 20100291551 | GENEMAP OF THE HUMAN ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (e.g. Crohn's Disease) and/or their response to a particular drug or drugs. | 11-18-2010 |
| Patent application number | Description | Published |
|---|
| 20100120627 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH PSORIASIS - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to psoriasis disease and/or their response to a particular drug or drugs. | 05-13-2010 |
| 20100120628 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH ADHD - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to ADHD disease and/or their response to a particular drug or drugs. | 05-13-2010 |
| 20100144538 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH SCHIZOPHRENIA - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to SCHIZOPHRENIA disease and/or their response to a particular drug or drugs. | 06-10-2010 |
